| Patient no. . | Age (years) . | Sex . | CTD disease . | Prior therapies . | Time to sirolimus (years) . | Sirolimus duration (m) . | Outcome . |
|---|---|---|---|---|---|---|---|
| 1 | 36 | F | SLE, APS | GCs, MMF, AZA | 15 | 18 | CR |
| 2 | 44 | F | SLE | GCs, FK506 | 13 | 17 | CR |
| 3 | 48 | F | SLE | GCs, MMF | 7 | 17 | CR |
| 4 | 47 | F | pSS | GCs, FK506 | 18 | 4 | NR |
| 5 | 35 | F | SLE | GCs, MMF | 2 | 12 | CR |
| 6 | 52 | F | SLE | GCs, CsA | 3 | 12 | CR |
| 7 | 31 | F | SLE | GCs, FK506 | 7 | 12 | CR |
| 8 | 43 | F | pSS | GCs, FK506, CsA, IVIG | 8 | 6 | NR |
| 9 | 39 | F | SLE | GCs, CTX | 8 | 6 | NR |
| 10 | 30 | F | SLE | GCs, MMF, CsA, TII | 15 | 5 | PR |
| 11 | 29 | F | SLE | GCs, FK506 | 7 | 9 | NR |
| 12 | 27 | F | CTD | GCs, CsA | 5 | 9 | CR |
| 13 | 54 | F | CTD | GCs, CsA | 5 | 8 | PR |
| 14 | 55 | F | pSS | GCs, AZA | 14 | 6 | NR |
| 15 | 18 | M | SLE | GCs, MMF, FK506, CsA | 3 | 6 | NR |
| 16 | 39 | F | CTD | GCs, CTX, FK506, CsA | 6 | 6 | NR |
| 17 | 20 | F | SLE | GCs, CTX, FK506, CsA, MMF, IVIg | 14 | 6 | NR |
| 18 | 18 | F | SLE | GCs, AZA, FK506 | 1 | 6 | CR |
| 19 | 31 | F | SLE | GCs, CsA, CTX | 6 | 6 | CR |
| 20 | 38 | F | SLE | GCs, HCQ | 4 | 6 | CR |
| Patient no. . | Age (years) . | Sex . | CTD disease . | Prior therapies . | Time to sirolimus (years) . | Sirolimus duration (m) . | Outcome . |
|---|---|---|---|---|---|---|---|
| 1 | 36 | F | SLE, APS | GCs, MMF, AZA | 15 | 18 | CR |
| 2 | 44 | F | SLE | GCs, FK506 | 13 | 17 | CR |
| 3 | 48 | F | SLE | GCs, MMF | 7 | 17 | CR |
| 4 | 47 | F | pSS | GCs, FK506 | 18 | 4 | NR |
| 5 | 35 | F | SLE | GCs, MMF | 2 | 12 | CR |
| 6 | 52 | F | SLE | GCs, CsA | 3 | 12 | CR |
| 7 | 31 | F | SLE | GCs, FK506 | 7 | 12 | CR |
| 8 | 43 | F | pSS | GCs, FK506, CsA, IVIG | 8 | 6 | NR |
| 9 | 39 | F | SLE | GCs, CTX | 8 | 6 | NR |
| 10 | 30 | F | SLE | GCs, MMF, CsA, TII | 15 | 5 | PR |
| 11 | 29 | F | SLE | GCs, FK506 | 7 | 9 | NR |
| 12 | 27 | F | CTD | GCs, CsA | 5 | 9 | CR |
| 13 | 54 | F | CTD | GCs, CsA | 5 | 8 | PR |
| 14 | 55 | F | pSS | GCs, AZA | 14 | 6 | NR |
| 15 | 18 | M | SLE | GCs, MMF, FK506, CsA | 3 | 6 | NR |
| 16 | 39 | F | CTD | GCs, CTX, FK506, CsA | 6 | 6 | NR |
| 17 | 20 | F | SLE | GCs, CTX, FK506, CsA, MMF, IVIg | 14 | 6 | NR |
| 18 | 18 | F | SLE | GCs, AZA, FK506 | 1 | 6 | CR |
| 19 | 31 | F | SLE | GCs, CsA, CTX | 6 | 6 | CR |
| 20 | 38 | F | SLE | GCs, HCQ | 4 | 6 | CR |
AZA: azathioprine; CH: Chinese herbs; CR: complete response; CsA: ciclosporin A; CTD-TP: connective tissue disease-related thrombocytopenia; CTX: cyclophosphamide; FK506: tacrolimus; GCs: glucocorticoids; IVIG: intravenous immunoglobulin G; NA: not available; NR: no response; PR: partial response; pSS: primary Sjögren's syndrome; TII: tripterygium glycosides.
| Patient no. . | Age (years) . | Sex . | CTD disease . | Prior therapies . | Time to sirolimus (years) . | Sirolimus duration (m) . | Outcome . |
|---|---|---|---|---|---|---|---|
| 1 | 36 | F | SLE, APS | GCs, MMF, AZA | 15 | 18 | CR |
| 2 | 44 | F | SLE | GCs, FK506 | 13 | 17 | CR |
| 3 | 48 | F | SLE | GCs, MMF | 7 | 17 | CR |
| 4 | 47 | F | pSS | GCs, FK506 | 18 | 4 | NR |
| 5 | 35 | F | SLE | GCs, MMF | 2 | 12 | CR |
| 6 | 52 | F | SLE | GCs, CsA | 3 | 12 | CR |
| 7 | 31 | F | SLE | GCs, FK506 | 7 | 12 | CR |
| 8 | 43 | F | pSS | GCs, FK506, CsA, IVIG | 8 | 6 | NR |
| 9 | 39 | F | SLE | GCs, CTX | 8 | 6 | NR |
| 10 | 30 | F | SLE | GCs, MMF, CsA, TII | 15 | 5 | PR |
| 11 | 29 | F | SLE | GCs, FK506 | 7 | 9 | NR |
| 12 | 27 | F | CTD | GCs, CsA | 5 | 9 | CR |
| 13 | 54 | F | CTD | GCs, CsA | 5 | 8 | PR |
| 14 | 55 | F | pSS | GCs, AZA | 14 | 6 | NR |
| 15 | 18 | M | SLE | GCs, MMF, FK506, CsA | 3 | 6 | NR |
| 16 | 39 | F | CTD | GCs, CTX, FK506, CsA | 6 | 6 | NR |
| 17 | 20 | F | SLE | GCs, CTX, FK506, CsA, MMF, IVIg | 14 | 6 | NR |
| 18 | 18 | F | SLE | GCs, AZA, FK506 | 1 | 6 | CR |
| 19 | 31 | F | SLE | GCs, CsA, CTX | 6 | 6 | CR |
| 20 | 38 | F | SLE | GCs, HCQ | 4 | 6 | CR |
| Patient no. . | Age (years) . | Sex . | CTD disease . | Prior therapies . | Time to sirolimus (years) . | Sirolimus duration (m) . | Outcome . |
|---|---|---|---|---|---|---|---|
| 1 | 36 | F | SLE, APS | GCs, MMF, AZA | 15 | 18 | CR |
| 2 | 44 | F | SLE | GCs, FK506 | 13 | 17 | CR |
| 3 | 48 | F | SLE | GCs, MMF | 7 | 17 | CR |
| 4 | 47 | F | pSS | GCs, FK506 | 18 | 4 | NR |
| 5 | 35 | F | SLE | GCs, MMF | 2 | 12 | CR |
| 6 | 52 | F | SLE | GCs, CsA | 3 | 12 | CR |
| 7 | 31 | F | SLE | GCs, FK506 | 7 | 12 | CR |
| 8 | 43 | F | pSS | GCs, FK506, CsA, IVIG | 8 | 6 | NR |
| 9 | 39 | F | SLE | GCs, CTX | 8 | 6 | NR |
| 10 | 30 | F | SLE | GCs, MMF, CsA, TII | 15 | 5 | PR |
| 11 | 29 | F | SLE | GCs, FK506 | 7 | 9 | NR |
| 12 | 27 | F | CTD | GCs, CsA | 5 | 9 | CR |
| 13 | 54 | F | CTD | GCs, CsA | 5 | 8 | PR |
| 14 | 55 | F | pSS | GCs, AZA | 14 | 6 | NR |
| 15 | 18 | M | SLE | GCs, MMF, FK506, CsA | 3 | 6 | NR |
| 16 | 39 | F | CTD | GCs, CTX, FK506, CsA | 6 | 6 | NR |
| 17 | 20 | F | SLE | GCs, CTX, FK506, CsA, MMF, IVIg | 14 | 6 | NR |
| 18 | 18 | F | SLE | GCs, AZA, FK506 | 1 | 6 | CR |
| 19 | 31 | F | SLE | GCs, CsA, CTX | 6 | 6 | CR |
| 20 | 38 | F | SLE | GCs, HCQ | 4 | 6 | CR |
AZA: azathioprine; CH: Chinese herbs; CR: complete response; CsA: ciclosporin A; CTD-TP: connective tissue disease-related thrombocytopenia; CTX: cyclophosphamide; FK506: tacrolimus; GCs: glucocorticoids; IVIG: intravenous immunoglobulin G; NA: not available; NR: no response; PR: partial response; pSS: primary Sjögren's syndrome; TII: tripterygium glycosides.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
